通过天眼查大数据分析，杭州迪视医疗生物科技有限公司共对外投资了1家企业，知识产权方面有商标 信息12条，专利信息51条。 天眼查信息显示，杭州迪视医疗生物科技有限公司的股东为：崔迪、杭州首望医疗科技合伙企业（有限 合伙）、Capricornus Investment HK Limited、杭州锐谷医疗技术有限公司、杭州上城创领聚源创业投资 合伙企业（有限合伙）。 1月19日，天眼查融资历程显示，杭州迪视医疗生物科技有限公司近日获得"A+轮"融资，涉及融资金额 数千万人民币，投资机构为「迪视医疗」完成数千万A2轮融资，老股东磐霖资本继续加码 | 磐霖 News。 资料显示，杭州迪视医疗生物科技有限公司法定代表人为崔迪，成立于2021年，位于杭州市，是一家以 从事研究和试验发展为主的企业。企业注册资本2664.374万人民币，并已于2026年完成了A+轮，交易 金额数千万人民币。 来源：市场资讯 ...

中新 "眼睛是心灵的窗户",在这个软组织结构精细、操作空间狭小的"窗户"上做手术,每一次手动操作都面临 巨大挑战。中国科学院自动化研究所1月19日向媒体通报,该所多模态人工智能系统全国重点实验室边桂 彬研究员团队最新成功研发出一款面向眼内空间的自主显微眼科手术机器人系统,并已验证临床可行 性。 ...

中信证券主要观点如下： 智通财经APP获悉，中信证券发布研报称，展望2026，预计算力发展具备高确定性，超节点技术将不断 升级，CSP大厂Capex会持续高增，看好算力芯片及系统级厂商投资机遇。大模型迭代步入深水区， Agent、多模态等方向能力持续提升，AI应用拐点已至；同时在出海拓展及内需政策支持下，AI应用公 司订单及收入增长有望提速。结构亮点方向，预计2026年起算力卫星建设逐步提速，星算产业化加快， AI医药电商不断创新，场景落地加快。建议关注四大主线：1)AI算力；2)AI应用；3)算力卫星；4)AI医 疗。 下一代大模型(Gemini 3.0/GPT5等)实质利好复杂推理、多模态类场景，助力AI产业走向规模化落地。国 内方面，模型大厂不断提升模型能力，独立模型厂商有较强研发能力的独立模型提供商脱颖而出。此 前，AI应用主要集中于Chatbot、Coding、搜索、客服等场景，该行认为，伴随模型能力提升，未来AI 的应用将更多走向广泛的多模态、Agent、具身智能等场景。海外需求看，2025年以来海外AI应用ARR 数据持续增长，商业化加速落地，国内AI应用公司加速布局海外市场，抢占全球AI应用市 ...

Group 1 - Hesai Technology's co-founders have established a new robotics company, Sharpa, aimed at developing general-purpose robots and core components, with over 100 employees [1] - Porsche's global sales for 2025 are projected to be 279,400 units, a 10% decrease year-on-year, with a significant decline of 26.28% in the Chinese market [4] - UTree Technology is expected to ship over 5,500 humanoid robots in 2025, with mass production exceeding 6,000 units [9] - OpenAI's annual revenue for 2025 is projected to exceed $20 billion, a significant increase from $6 billion in 2024, driven by an expansion in computing power [13] - The UK government has announced a substantial subsidy plan for electric trucks, with a total budget of £318 million, aiming to boost the adoption of electric vehicles [19] Group 2 - The HuRun Research Institute's report on China's AI companies ranks Cambricon first with a valuation of 630 billion yuan, reflecting a 165% increase from the previous year [10] - Anker Innovations and Feishu have launched the AI hardware product "Anker AI Recording Bean," which features advanced recording capabilities and is priced at 899 yuan [21] - Alibaba Health has introduced the AI product "Hydrogen Ion," designed for medical professionals, which aims to minimize hallucination rates in AI responses [23] - Xiaopeng Motors has successfully developed the first robot based on automotive standards, marking a significant milestone in their robotics initiative [24] - Apple's iPhone shipments surged by 28% during the holiday season, regaining market leadership in China despite overall market declines [30]

Core Viewpoint - The development of an autonomous microscopic ophthalmic surgical robot system by the Chinese Academy of Sciences aims to enhance the precision, safety, and consistency of intraocular procedures, addressing the challenges faced in delicate eye surgeries [1][2]. Group 1: Technological Advancements - The newly developed robot can autonomously perform subretinal and intravascular injections within the eye, significantly improving the accuracy and safety of retinal injections while minimizing iatrogenic damage [2][5]. - The research team has innovatively constructed core algorithm modules for three-dimensional spatial perception, precise cross-scale positioning, and trajectory control, enhancing the robot's operational capabilities [2][3]. Group 2: Clinical Validation - In experiments involving ocular prosthetics, ex vivo pig eyes, and live animal eyes, the robot achieved a 100% success rate in injections, with average positioning errors reduced by 79.87% compared to manual operations and 54.61% compared to doctor-assisted robotic operations, demonstrating superior safety and precision [5]. Group 3: Implications for the Industry - This research opens a new technological pathway for the autonomy of intraocular surgeries, potentially leading to intelligent and precise upgrades in ophthalmic surgical treatments, with significant applications in telemedicine and complex environments [6].

Group 1: Event Overview - The 18th Entrepreneurial Conference and the Future Unicorn Conference were successfully held in Beijing, focusing on the theme "Only the Timeless Thrive" [1] - The conference released the "2025 Global Unicorn Enterprises Observation Report" and the "2025 China Corporate Venture Capital Development Report" [1] - The "2025 Entrepreneurial 100 Future Unicorn" list was unveiled, highlighting 100 high-potential tech companies valued between $100 million and $1 billion [1] Group 2: Unicorn Growth Insights - It is projected that 120 new unicorns will emerge globally in 2025, a 9.1% increase year-on-year, with the U.S. contributing 73 and China 22 [2] - By the end of 2025, there will be 1,949 existing unicorns globally, with 903 in the U.S. and 509 in China [2] - The AI sector continues to lead in new unicorn development, with 53 AI unicorns globally, accounting for 44.2% of the total [2] Group 3: Investment Trends and Predictions - The investment environment is shifting from U.S.-led to state-owned capital dominance, but opportunities for innovation will continue to attract capital [5] - The Chinese capital market is expected to experience a significant influx of funds in 2026, with a shift in investment logic towards hard technology and scientific entrepreneurs [5] - The Hong Kong stock market is anticipated to become a primary financing avenue for startups, supported by recent regulatory innovations [11] Group 4: Industry Challenges and Strategies - Companies are encouraged to focus on customer value and sustainable growth rather than merely chasing valuations [7] - The semiconductor industry is characterized by high investment and long cycles, requiring investors to have a strong belief in the industry [9] - The medical sector emphasizes a long-term mindset, focusing on core technologies and clinical value to drive innovation [24] Group 5: Global Expansion and Localization - Chinese tech companies are transitioning from exporting goods to expanding production tools and manufacturing overseas, facing challenges such as compliance and talent shortages [22] - Companies should leverage domestic advantages and pursue localized operations to navigate global markets effectively [22] Group 6: Future Unicorn Evaluation - The "2025 Entrepreneurial 100 Future Unicorn" list evaluates companies based on long-term growth potential across five dimensions, revealing a significant increase in AI companies [16] - The average valuation of listed companies reached 2.57 billion, with 61% having completed five or more funding rounds [16] Group 7: Capital and Innovation Dynamics - The report indicates a significant drop in new CVC fund registrations, with a concentration of investment activities in major cities [28] - CVCs participated in 40% of large investment events, with a notable success rate in IPO exits [28] - The focus on hard technology and robust cash flow management is essential for navigating the evolving investment landscape [28]

在"一线"，海南自贸港"零关税"等政策高效实施，借助径予放行便利化通关模式，海南口岸进口货物迎来通 关效率与成本双优化，有力支撑自贸港产业升级。1月9日，一批进口的3万吨矿产品运抵海南洋浦港，该批矿 产以"'零关税'+径予放行"模式入境，全程通关流程简化、时效提升。该批货物进口企业相关负责人表示，径 予放行让原料进口通关更高效，"零关税"政策大幅降低企业采购成本，双重利好让企业能更快推进产能释 放。 海南自贸港封关首月，进口"零关税"货值达7.5亿元 离岛免税购物金额超48亿元 | | | 2025年12月18日至2026年1月17日 | | | --- | --- | --- | --- | | | 海口海关在"一线"监管 | 海口海关共监管 | 海口海关共监管离岛免税购物金 | | 海南新增备案 | "零关税"货物75亿元,在 | 海南空港口岸进出境 | 额48.6亿元,同比增长46.8%;购物 | | 外贸企业5132家 | "二线"监管销往内地的加工 | 人员31万人次,同 | 人数74.5万人次,同比增长30.2%; | | | 增值免关税货物 8586.7万元 | 比增长48.8% | 购物件数3 ...

中证报中证网讯（记者 傅苏颖）1月19日，中国证券报记者获悉，阿里健康AI产品"氢离子"已完成内测 并开放下载，该产品主要面向临床、科研领域的医生群体。 据了解，"氢离子"主打"低幻觉、高循证"核心能力，所有回答均有权威出处，支持一键溯源、直达信 源，致力于打造医疗领域幻觉率最低的AI助手。 此前，阿里巴巴已通过通义千问、蚂蚁阿福布局C端健康服务。而高门槛、高专业性的严肃医疗场景应 用，则交由阿里健康承接。至此，阿里在医疗健康领域的AI布局已实现"C+D"端的完整布局，其医疗AI 版图已然补齐。 ...

1月19日，杭州迪视医疗生物科技有限公司（简称"迪视医疗"）宣布完成数千万元A2轮融资。本轮融资 由达晨财智领投，老股东磐霖资本持续追加，距离公司完成上一轮由磐霖资本领投的融资时隔仅半年时 间。该笔资金将加快推动迪视医疗超显微手术机器人从技术领先走向市场普及。 ...

据悉，阿里健康重磅AI产品"氢离子"已完成内测并开放下载。 经多方信源证实，该产品已进入实际应用阶段，主要面向临床、科研领域的医生群体。据了解，"氢离子"主打"低幻觉、高循证"核心能力，所有回答均有权 威出处，支持一键溯源、直达信源，致力于打造医疗领域幻觉率最低的AI助手。 此前，阿里健康财报中也曾透露，其自研医学大模型正在积极探索在严肃医疗领域的应用场景，致力增强模型在临床决策、临床科研等关键环节的AI循证 能力。此次，"氢离子"正是该模型能力的首个产品化体现。 多位参与内测的医生反馈，"氢离子"在循证问答、证据整合与分析总结等任务中表现出高度准确度，尤其在临床、科研语境下的智能检索和中英文献研读方 面，更贴合国内医生习惯。其产品逻辑与海外大热的OpenEvidence相似，但在本地化体验上更具优势。 此前，阿里巴巴已通过通义千问、蚂蚁阿福布局C端健康服务。高门槛、高专业性的严肃医疗场景应用，则交由深耕医疗健康领域十余年的阿里健康承接。 至此，阿里在医疗健康领域的AI布局已实现"C+D"端的完整布局，其医疗AI版图已然补齐。 小 即 阿托伐他汀 财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：钟离 ...